Figure 3
PD901 and PTT synergistically combine to yield improved treatment outcomes for MPNSTs in vitro.
(a) M2 cells treated with low and high doses of PD901 and PTT show significantly decreased cell viability in combination therapy (PD901 plus PTT)-treated groups relative to either therapy administered individually under identical conditions after 24 h. LOW PD901: 0.125 μM; LOW PTT 0.005 mg/mL + 1.5 W/cm2 808 nm laser for 10 minutes; LOW Combo: both LOW PD901 + LOW PTT treatments; HIGH PD901: 1.0 μM; HIGH PTT 0.05 mg/mL + 1.5 W/cm2 808 nm laser for 10 minutes; HIGH Combo: both HIGH PD901 + HIGH PTT treatments. Data expressed as mean ± standard deviation (n ≥ 3/group). *p < 0.05. (b) M2 cells treated with vehicle, HIGH PD901, HIGH PTT, HIGH Combo for 4 h, and subsequently harvested, lysed, and probed for p-ERK, exhibit complete eradication of p-ERK expression in both the PD901 and HIGH Combo groups, and a clear decrease in the HIGH PTT-treated group. Actin was used as a loading control. (c) PD901 synergistically combines with PTT to decrease M2 cell viability in vitro over either treatment alone at equivalent doses. 50,000 M2 cells were treated with increasing doses of PD901, PTT, or combination, and viability was measured after 24 h by CellTiter-Glo viability assay (Promega). Data points represent means ± standard deviation; n = 3 per group.
